Background: Grass pollen subcutaneous immunotherapy (SCIT) is associated with induction of serum IgG 4 -associated inhibitory antibodies that prevent IgE-facilitated allergen binding to B cells.
compared to 66% (P < .001) in serum and was reversed after depletion of IgG. Both nasal fluid (r 5 20.69, P 5 .0005) and serum (r 5 20.552, P 5 .0095) blocking activity correlated with global symptom improvement. IL-10 1 regulatory B cells were increased in season compared to out of season in the SCIT group (P < .01). Conclusion: For the first time, we show that nasal IgG 4 Grass pollen injection allergen immunotherapy (AIT) is an effective treatment for seasonal allergic rhinitis (SAR), an IgE-mediated disease that causes chronic inflammation of the nasal mucosa. [1] [2] [3] [4] [5] AIT is associated with a reduction in symptoms, 4, 6, 7 less use of rescue medications, and improvement in quality of life. [8] [9] [10] [11] [12] It induces clinical and immunologic allergen-specific immune tolerance and thus confers a long-lasting clinical benefit. [1] [2] [3] [4] 13, 14 However, a minority of the patients do not respond optimally to AIT, 13, 15 indicating a need for biomarkers as surrogate end points both for early identification of responders and as for end points of clinical trials. 15 Therefore biomarkers have an important role in AIT personalized medicine. 15, 16 It is widely accepted that IgG antibodies, especially IgG 4 , play a central role in the mechanism of AIT. Immediately after the start of AIT, an increase in the range of 10-to 100-fold in the concentrations of IgG 1 and particularly that of IgG 4 is observed. 17, 18 These antibodies have been shown to be produced by regulatory B (Breg) cells that predominantly secrete IL-10, favoring antibody class-switching from IgM or IgE to IgG 4 . 19 The correlation between serum IgG 4 levels and clinical outcomes is highly variable, and results from several clinical studies have been contradictory. 20, 21 IgG 4 has 2 main effects in the mechanism of AIT, leading to tolerance. First, IgG 4 acts as a neutralizing antibody that competes with IgE for allergen binding and thus acts as a blocking antibody that prevents the activation and degranulation of effector cells. 22, 23 Second, IgG 4 blocks IgE-facilitated binding of allergen-IgE complexes to B cells, a surrogate and rate-limiting step for IgE-facilitated T-cell activation. In allergic patients allergen-IgE complexes bind to the low-affinity IgE receptor FcεRII (CD23) on the surfaces of B cells. Subsequently, activated B cells present processed allergen peptides on the surfaces of HLA class II molecules to the relevant peptidespecific T-cell clones along with costimulation, thereby resulting in T-cell activation, proliferation, and cytokine production. Thus sera obtained from subjects receiving birch and grass pollen immunotherapy inhibited IgE-facilitated presentation of allergen by B cells to allergen-specific T-cell clones. [22] [23] [24] The majority of this inhibitory activity for IgE-FAB present in postimmunotherapy serum resides within the IgG 4 subclass, as shown by affinity chromatography. 25, 26 We and others have shown in several clinical studies that serum inhibitory activity for IgE-FAB can correlate with the clinical response to grass and birch AIT up to 2 years after discontinuation of AIT. 27 although its functional role in the mechanism for immunotherapy remains unclear.
We hypothesized that immunotherapy efficacy is associated with induction of blocking antibody production locally in the nasal mucosa. First, we demonstrate the specificity and function of nasal and serum grass pollen specific IgE and specific IgG 4 in and out of the grass pollen season in immunotherapy-treated patients (AIT), untreated allergic patients (SAR group), and nonatopic control (NA) subjects. Second, we report the relationship between IL-10 1 Breg cells and peripheral and nasal IgG 4 . Finally, we report that local functional antibody responses correlate with clinical response to injection immunotherapy.
METHODS Subjects
A cross-sectional controlled study of grass pollen subcutaneous immunotherapy (SCIT) was conducted outside (September-February) and during (June-August) the grass pollen season. Ten patients with moderate-severe SAR treated with SCIT (Phleum pratense [Phl p]; Alutard SQ, ALK-Abell o, Hørsholm, Denmark) were recruited, along with 13 immunotherapy-naive (untreated) patients with SAR and 12 NA subjects (Table I) . Inclusion and exclusion criteria can be found in the Methods section in this article's Online Repository at www.jacionline.org. All enrolled study participants completed the study. Blood samples were collected outside (September-February) and during (May-July) the grass pollen season.
The study was approved by the national research ethics committee (South West London committee, REC3) and the Research Office of the Royal Brompton and Harefield NHS Foundation Trust. Written informed consent was obtained from all patients before collecting nasal and blood samples. Nasal fluid and blood samples from all participants were anonymized and blinded before laboratory processing. All research laboratory staff were blinded, and all experiments were performed blind. Data were locked before unblinding the results. All analysis was performed on the availability of nasal fluid samples from participants.
Rhinoconjunctivitis Total Symptom Scores, Global Evaluation scores, and Mini-Rhinitis Quality of Life Questionnaire scores Rhinoconjunctivitis Total Symptom Score (RTSS) were taken from patients during the pollen season. Individual nasal symptoms, itching, sneezing, runny nose, blocked nose, and eye redness and tears were scored on a 4-point scale. Changes in symptom severity compared to that of before treatment were quantified by using a retrospective global evaluation score. Nasal fluid and serum collection in and out of the grass pollen season Nasal fluid was collected from a single foam sponge (Zuschnitt Schaumstoff RG27 grau, ISO 5999, 1982 sponge; Gummi-Welz GmbH & Co, Neu-Ulm, Germany) inserted into each nostril under direct vision by using sterile forceps and left in place for 5 minutes. Sponges were then placed above a microfilter within a Spin-X 0.22-mm centrifuge tube (Costar; Corning, Corning, NY) and kept briefly on ice (see the Methods section in this article's Online Repository for further description).
Immunoglobulin measurements in nasal fluid and serum
Total IgE levels were measured in serum by using the ImmunoCAP100 system (Phadia, Uppsala, Sweden), according to the manufacturer's instructions. Levels of sIgE and sIgG 4 to grass pollen components in nasal fluid and serum were measured by using the Immuno Solid Allergen Chip (ISAC) array (Thermo scientific, Winsford, United Kingdom), according to the manufacturer's protocol, and analyzed with Phadia MIA software.
CD23-mediated IgE-FAB
Using an in vitro IgE-Facilitated Allergen Binding (IgE-FAB) assay, we assessed the ability of IgE in nasal mucosa and serum to facilitate the cooperative binding of allergen-IgE complexes to CD23 on the surfaces of B cells carried out as previously described (see the Methods section in this article's Online Repository for further description). 29 
Inhibition of CD23-mediated IgE-FAB
IgE-FAB to B cells was performed, as previously described. 15, [29] [30] [31] [32] Briefly, serum from a grass pollen-sensitized donor (Phl p sIgE >100 kU/L) was incubated with 1 mg/mL Phl p in the presence or absence of an equal volume of nasal fluid or serum from study patients for 1 hour at 378C. EBV-transformed B cells (100,000 cells per test) were added for 1 hour at 48C and washed. Binding of allergen-IgE complexes to the CD23 receptor on the surfaces of B cells was detected by using phycoerythrin-labeled anti-human IgE antibodies (Miltenyi Biotech, Auburn, Calif) and acquired with the BD FACSCanto II (BD Biosciences, Rockville, Md). Data were analyzed by using FACSDiva software (BD Biosciences). Binding of allergen-IgE complexes to B cells and inhibition relative to indicator serum from a patient with grass pollen allergy was calculated by using the following formula:
% Relative allergen IgE complex binding to B cells 5 % IgE FAB using indicator and immunotherapy serum % IgE FAB indicator serum only 3100
IgG depletion from nasal fluid and serum from patients undergoing AIT
IgG depletion from nasal fluid samples and sera from SCIT-treated patients was carried out by using Proteus Protein G Antibody Purification Mini-Kits (BioRad, Oxford, United Kingdom), according to the manufacturer's protocol (see the Methods section in this article's Online Repository for further description).
Quantification of Breg cells
Heparinized blood diluted 1:1 with RPMI 1640 media (Life Technologies, Paisley, United Kingdom) was layered on 30% Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) density gradient and centrifuged for 25 minutes at 2200 rpm at room temperature. The PBMC layer was collected, washed, and resuspended in RPMI 1640 medium. Cell viability of greater than 97% was assessed by using trypan blue exclusion. B cells were isolated from PBMCs obtained from NA subjects, patients with SAR, and patients undergoing SCIT using the CD19 
Statistical analysis
The 2-tailed Mann-Whitney test determined statistical differences between individual groups. The Wilcoxon signed-rank test was used for within-group comparisons. One-way ANOVA with Friedman correction for repeated nonparametric measurements was performed where comparison against baseline measurement was required. Correlations between symptom scores and inhibitory activity of serum and nasal fluid was assessed by using the Spearman rank test. Analyses were performed by using Prism software (GraphPad Software, La Jolla, Calif), with P values of less than .05 considered as significant.
RESULTS

Symptom scores
RTSSs were significantly lower in the SCIT group compared to untreated SAR (P 5 .009; Fig 1, A) . NA subjects did not exhibit any seasonal symptoms (Fig 1; patients' demographics are presented in Table I ). Retrospective global evaluation scores revealed a decrease in overall severity, which was greater in the SCIT group compared with that in the untreated SAR group (P 5 .006; Fig 1, B) . The overall mean Mini-Rhinitis Quality of Life Questionnaire scores and some individual parameters observed were lower in the SCIT group compared with those in the SAR group (P 5 .024; Fig 1, C , and see Tables E1 and E2 in this article's Online Repository at www.jacionline.org).
Grass pollen sIgE levels in serum and nasal fluid in the SAR, NA, and SCIT groups Phl p 1 and Phl p 5 (major grass pollen allergens) sIgE levels were measured in nasal fluid and serum from NA subjects, patients with SAR, and subjects undergoing SCIT. Nasal and serum Phl p 1 sIgE levels were greater in patients with SAR compared with NA subjects (all, P < .001; Fig 2) . However, there was no difference in the levels of nasal and serum Phl p 1 sIgE in patients undergoing SCIT compared with the SAR group. Furthermore, nasal and serum Phl p 5 sIgE levels were higher in patients with SAR compared with NA subjects (all, P < .001; Fig 2, A-B) . In contrast, Phl p 5 sIgE responses were lower in the SCIT-treated patients in nasal fluid compared with patients with SAR (P < .001; Fig 2, A) and in serum (P 5 .073; Fig 2, B) . IgG depletion resulted in an increase in nasal and serum levels of Phl p 1 and Phl p 5 sIgE in each SCIT-treated patient (Fig 2, C and D) . However, this did not influence the difference in the levels of sIgE to Phl p 1 and Phl p 5 between the SCIT and SAR groups.
sIgE in nasal fluid is functional and forms cooperative allergen-IgE binding to CD23 on the surfaces of B cells
After identifying the induction of sIgE in the local mucosa in patients with SAR, we determined the functional role of sIgE antibodies by assessing their ability to mediate CD23-dependent IgE-allergen complexes binding to B cells (Fig 3, A  and B) . A dose-dependent response of allergen-IgE complexes binding to CD23 on the surfaces of B cells was observed in the presence of Phl p but not an irrelevant birch pollen allergen (Fig 3, C and D) . Optimal binding was observed at 1 mg/mL Phl p (Fig 3, C) . IgE dependency was assessed by diluting nasal fluid samples from patients with grass pollen allergy. A dilution-dependent linearity of allergen-IgE complexes binding to B cells was observed (Fig 3, E) . The requirement of the low-affinity IgE receptor CD23 for allergen-IgE complexes binding to B cells was also investigated. Preincubation of B cells with increasing concentrations of anti-CD23 antibody resulted in a concentration-dependent decrease of allergen-IgE binding (Fig 3, F) .
SCIT induces nasal immunoreactive and functional IgG 4 antibodies with inhibitory activity for IgEmediated responses
Levels of immunoreactive and functional sIgG 4 to grass pollen components were measured in nasal fluid samples and sera in and out of the pollen season from NA subjects, patients with SAR, and SCIT-treated patients. Nasal Phl p 1 and 5 sIgG 4 levels were increased in patients with SAR during the pollen season compared with those out of season (all, P < .01; Fig 4, A) . SCIT-treated group also had increased levels of nasal Phl p 1 and 5 sIgG 4 in season compared with those out of season (all, P < .05; Fig 4, A) . Increases in Phl p 1 and 5 sIgG 4 levels were greater in patients undergoing SCIT compared with patients with SAR (all, P < .01). NA subjects did not exhibit any increase in Phl p 1 and 5 sIgG 4 levels in season compared with those out of the pollen season (data not shown). Serum Phl p 1 and 5 sIgG 4 levels did not increase in the SAR and SCIT group. However, levels were higher (all, P < .01; Fig 4, B) in the SCIT group compared with the SAR group. Seasonal allergen exposure did not affect serum IgG 4 levels (Fig 4, B) . Interestingly, during grass pollen season, the Phl p 5 sIgG 4 /sIgE ratio was significantly greater in nasal fluid samples compared with levels in serum in SCIT-treated patients (P < .05; see Cooperative allergen-IgE binding to B cells was decreased in SCIT-treated patients in and out of season, compared to SAR. Out of season, the nasal inhibitory activity of SCIT-treated patients was reduced to 74% (P < .001), and a further reduction was observed during the season, reaching 93% (P < .001; Fig 4, C) . Similarly, the functional IgG 4 response from peripheral blood was also reduced to 66% (P < .001) in season and 60% (P < .001) out of season (Fig 4, D) . This reduction in allergen-IgE binding to B cells correlated with the increased levels of IgG 4 in SCITtreated patients.
IgG depletion from SCIT samples was performed to further elucidate the protective role of IgG for having a suppressive effect on allergen-IgE complexes binding to B cells. Depletion of total IgG from SCIT samples resulted in higher binding of allergen-IgE complexes to B cells (P <.001) compared with non-depleted samples from the SCIT group and restored the level of IgE-FAB binding close to that observed for the untreated SAR samples (Fig 4,  E) . When the IgG eluate from the column was added back to the IgG-depleted complex mixture, inhibition of allergen-IgE complex binding to B cells was again seen and comparable with that observed for the non-depleted SCIT serum. In contrast, this allergen-IgE complex binding inhibitory activity was not restored by addition of control purified IgG 4 from a nonatopic donor (ie, not specific to grass pollen). Levels of nasal Phl p 5 sIgG 4 inversely correlated against nasal IgG-associated inhibitory activity (r 5 20.85, P < .0001). However, the magnitude of this association was less in serum (r 5 20.55, P 5 .0095; see Table II ).
Influence of natural grass pollen allergen exposure on IL-10 1 Breg cell subsets in patients undergoing SCIT, patients with SAR, and NA subjects
IL-10
1 Breg cell subsets were quantified in and out of the grass pollen season in NA subjects, patients with SAR, and SCIT-treated patients. Numbers of IL-10 1 CD19 (Fig 1, A) and serum (Fig 1, B) from NA subjects, patients with SAR, and SCIT-treated patients by using the ISAC assay. Data are shown as violin plots with individual data (open blue circles, NA subjects; orange circles, patients with SAR; and green circles, patients undergoing SCIT), quintile box plots, and data distribution. C and D, Depletion of IgG from nasal fluid and serum from SCIT-treated patients. Data are shown as bar charts for individual data (white bar, SCIT; green bar, IgG-depleted SCIT samples). P values were obtained by using the 2-tailed Mann-Whitney test.
compared with out of season in SCIT-treated patients (all P < .01, Fig 5) . hi Breg cells compared with the NA group (P < .05 and P < .001, respectively; Fig 5) . Moreover, numbers of IL-10 
Functional nasal IgG levels correlate with clinical response to treatment
The relationship between the clinical response to grass pollen SCIT was measured based on global improvement, RTSSs, and visual analog scale (VAS), along with IgG-associated inhibitory activity assessed through IgE-FAB, Phl p 5 sIgG 4 , and the Phl p 5 sIgG 4 /sIgE ratio in nasal fluid and serum.
Levels of Phl p 5 sIgG 4 in nasal fluid were correlated with global improvement (Spearman r 5 0.49, P 5 .024) but inversely correlated with RTSSs (r 5 -0.59, P 5 .005) and VASs (r 5 -0.58, P 5 .0091). Serum Phl p 5 sIgG 4 levels did not correlate with global improvement (r 5 -0.37, P 5 .0955), RTSSs (r 5 -0.37, P 5 .09), and VASs (r 5 -0.06, P 5 .766) ( Table II) (Table II) . IgG-associated inhibitory activity in nasal fluid inversely correlated with global improvement (r 5 20.69, P 5 .0005), RTSSs (r 5 0.62, P 5 .0028), and VASs (r 5 0.57, P 5 .007). However, IgG-associated inhibitory activity in serum had a modest inverse correlation against global evaluation (r 5 20.55, P 5 .0095), RTSSs (r 5 0.50, P 5 .02), and VASs (r 5 0.31, P 5 .169) (Table II) . Cooperative binding of allergen-IgE to B cells was measured using the FAB assay. E, IgE dependency and linearity were assessed by diluting nasal fluid obtained from patients with grass allergy. F, CD23 dependency was tested by pretreating EBV-transformed B cells with anti-CD23 blocking antibody at varying concentrations. Allergen-IgE complex binding to B cells was detected by using nasal fluid obtained from only 6 of 13 patients with grass allergy caused by insufficient volumes of nasal fluid from the rest of the patients in the presence of 1 mg/mL allergen. Comparisons with baseline measurements were determined by using 1-way ANOVA with Friedman correction for repeated nonparametric measurements. *P < .05, **P < .01, and ***P < .001, respectively.
DISCUSSION
For the first time, we have shown that grass pollen-specific immunotherapy, in particular SCIT, is associated with induction of local (nasal) and functional antibodies that inhibit IgE-FAB in the nasal mucosa. Furthermore, we demonstrated that inhibitory activity against IgE in nasal fluid from SCIT-treated patients correlates better with clinical outcome than the inhibitory activity of serum samples, highlighting its potential as a novel biomarker for monitoring treatment effect. Moreover, we have demonstrated that grass pollen SCIT induces an increase in numbers of IL-10 1 Breg cells that correlates with the increase in IgG 4 levels. Our findings suggest that the functional inhibitory activity in both nasal fluid and serum is dependent on the functionality of grass pollen sIgG 4 blocking antibodies, given that depletion of IgG in SCIT nasal fluid and serum samples led to recovery of allergen-IgE complexes binding to CD23 on B cells.
Allergy is characterized by an increase in serum sIgE levels in the context of symptoms on exposure to the relevant allergen. Our findings show a seasonal increase in levels of local sIgE in the nasal fluid of allergic patients compared to healthy control subjects. Furthermore, sIgE in the nasal mucosa is functional and has the ability to mediate CD23-dependent IgE-facilitated allergen binding and presentation by B to T cells. AIT did not diminish levels of sIgE in the nasal mucosa. However, depletion of IgG resulted in an increase in levels of IgE, suggesting the potential of IgG to compete with IgE. 33 AIT is known to be associated with the induction of sIgG 4 antibodies. 2, 22, 34 This increase is likely to be under the influence of newly induced IL-10-producing regulatory T cells, as well as Breg cells. 22, 34 In this study we illustrated that both nasal fluid and serum from SCIT-treated patients inhibited allergen-IgE complex binding to B cells, as measured through the IgE-FAB assay. In addition, we also illustrated that inhibition of IgE-FAB to B cells in nasal fluid and serum was dependent on the duration of the SCIT treatment. A greater inhibition of allergen-IgE complex binding to B cells was observed in nasal fluid compared to serum, and this is likely due to the higher amount of sIgG 4 antibodies and a high IgG 4 /IgE ratio. (Fig 4, A) and serum (Fig 4, B) from patients with SAR and SCIT-treated patients. Data are shown as violin plots with individual data (open blue circles, NA subjects; orange circles, patients with SAR; and green circles, SCIT-treated patients), quintile box plots and data distribution, and means (SEMs). C and D, Cooperative allergen-IgE binding to B cells and inhibitory activity for IgE-FAB was measured in nasal fluid (Fig 4, C) and serum (Fig 4, D) from patients with SAR and SCIT-treated patients in season (IS) and out of season (OS). E, Binding of allergen-IgE complexes to B cells following IgG depletion was determined using IgE-FAB Assay. Data are represented as bar charts (orange bar, untreated SAR group; blue bar, SCIT-treated group). P values were obtained by using the 2-tailed Mann-Whitney test (between groups) and the Wilcoxon signed rank test (within groups). *P < .05, **P < .01, and ***P < .001, respectively.
Our study confirms the induction of sIgG 4 not only in serum but also in nasal fluid of grass pollen SCIT-treated participants, specific to several components of grass pollen, when measured semiquantitatively with the solid-phase ISAC assay. However, a limitation of this assay is that it provides a semiquantitative measurement of IgG 4 in ISAC units, as opposed to total quantified levels that can be measured by using ImmunoCAP. However, ISAC was preferred because of its use in smaller sample volumes. Furthermore, allergen-sIgG 4 can compete with sIgE with allergen for allergen binding within the assay, which might lead to detection of lower levels of sIgE than actual levels.
In spite of this, SCIT-treated patients demonstrated significantly increased Phl p 1 and Phl p 5 sIgG 4 levels in both nasal fluid and serum despite similar levels of Phl p 1 and Phl p 5 sIgE in both groups. The Phl p 5 sIgG 4 /sIgE ratio was found to be significantly greater in nasal fluid when compared with that in serum. A previous study identified local nasal increases in sIgG 1 but not sIgG 4 levels by using ELISA in patients with birch allergy who received SCIT with a recombinant birch vaccine. 18 In addition to this, a previous study reported that ragweed-specific IgA and sIgG antibodies could inhibit basophil histamine release. 35 Despite these previous findings, the inhibitory effect of serum from SCIT-treated patients that arises from the functional CD23-mediated blocking activity of sIgG 4 has not been assessed in nasal fluid. Nasal fluid and serum samples from SCIT-treated patients were depleted of IgG to test the role of sIgG antibodies in eliciting these blocking effects. In both serum and nasal fluid, depletion resulted in significant recovery of allergen-IgE complex binding to B cells. We conclude that functional inhibitory activity in nasal fluid and serum is IgG dependent. We confirmed that the previously described mechanisms of IgG 4 blocking activity are present not only in serum (Fig 5, B ) and IL-10 1 CD19 1 CD24 hi CD38 hi (Fig 5, C) Breg cells in NA subjects (n 5 12), patients with SAR (n 5 13), and SCIT-treated patients (n 5 10) in and out of the allergen season. P values were obtained by using the Wilcoxon signed rank test (within groups) and 2-tailed Mann-Whitney test (between groups). *P < .05, **P < .01, and ***P < .001, respectively. but extend to nasal fluid harvested directly from the nasal mucosa. The SAR group also showed a seasonal increase in sIgG 4 levels in nasal fluid, although this increase was very modest compared to the SCIT-treated group. Immunotherapy exerts its effect in the target organ, and therefore it is paramount to assess the immunomodulatory effect in the nasal mucosa. In our study IgG 4 blocking antibodies measured in nasal fluid correlated more closely with clinical efficacy (ie, RTSS or VAS) compared to serum. These findings clearly highlight the need to measure IgG 4 and IgG 4 blocking activity during AIT in the target organ rather than in serum. Although serum IgG 4 levels can reflect immunologic response and treatment compliance. It is also important to note that this was a pilot study, and a large study of SCIT is needed to confirm nasal IgG 4 blocking antibody as a biomarker of SCIT.
Some studies have suggested that IL-10 and Breg cells are responsible for the observed increase in sIgG 4 levels. 36 We have also confirmed an increase in the population of IL-10 1 Breg cell subsets (CD19
1
CD24
hi CD38 hi and CD19 1 CD5 hi CD1d 1 ) in the patients receiving SCIT compared with the SAR group. We have shown that the proportion of Breg cells were lower in patients with SAR compared with NA subjects and that grass pollen SCIT was associated with the restoration of Breg cell subsets to levels near those in NA subjects.
We have also demonstrated a correlation between IL-10 Breg cell counts and peripheral IgG 4 levels. It would be insightful to reproduce these findings by enumerating allergen-specific Breg cells. However, identifying these cells is technically challenging because the frequency of these cells is extremely low in peripheral blood, which makes it very challenging to acquire sufficient cells by using flow cytometry to have reliable and reproducible data. To further address the functionality of Breg cells, we showed that IL-10 1 Breg cells were able to inhibit allergen-driven T-cell proliferation and cytokine (IL-5 and IL-13) production and that this inhibition was dependent on IL-10. We further highlight that IL-10-producing Breg cells were induced by SCITwhen compared with those in patients with SAR over a period of 12 to 24 months of treatment.
We have identified a correlation between functional activity in nasal fluid and clinical response treatment. We confirmed our previously reported correlation of the functional inhibitory activity of serum IgG 4 and symptom scores and clinical outcome. 2 The correlation between functional inhibition by nasal fluid for RTSS and global evaluation was stronger than the correlation between functional inhibition by serum for RTSS and global evaluation, suggesting that functional activity in nasal fluid represents a more predictive and accessible biomarker for monitoring clinical responses to treatment. Further studies with larger cohorts are needed to support these findings.
This cross-sectional study, performed in and out of the pollen season, provides us with a snapshot regarding the change in biomarkers after treatment. A prospective study is needed to investigate changes in levels of baseline biomarkers before and after treatment with AIT. This will provide us with a clearer indication as to whether the biomarkers identified in this study are a true marker of treatment response.
In conclusion, for the first time, we report that after grass pollen SCIT, both local IgE inhibitory activity and allergen-sIgG 4 antibody levels were increased in nasal fluid. The increase in IgG 4 and IgE inhibitory activity in nasal fluid correlated more closely with clinical outcomes when compared with serum samples. Larger clinical studies with samples before/after treatment will determine whether changes in local IgG-associated IgE-inhibitory activity will be applicable as a potential biomarker to predict clinical response to treatment in individual patients.
Key messages
d Grass pollen-specific immunotherapy, in particular SCIT, is associated with induction of local (nasal) and functional antibodies that inhibit IgE-FAB in the nasal mucosa.
d Inhibitory activity against IgE in nasal fluid from SCIT-treated patients correlates more closely with clinical outcome than the inhibitory activity of serum samples, highlighting its potential as a novel biomarker for monitoring treatment effect.
d Grass pollen SCIT induces an increase in IL-10 1 Breg cells that correlates with the increase in IgG 4 levels. 
